Study of people with TTR amyloidosis worldwide
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This is an observational study (no study drug) for people with transthyretin (TTR)–mediated amyloidosis, including people who carry certain gene changes before symptoms begin. It may help researchers better understand how the disease affects health over time and what to measure in future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with TTR-mediated amyloidosis, or you have a known disease-causing TTR gene variant (for the pre-symptomatic group).
- For the Germany group only: you are being treated according to the approved treatment instructions in Germany.
- You are not currently enrolled in any other clinical trial testing an investigational (study) medication.
- You may be asked for study visits and health updates as part of routine observation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the health records of people with ATTR amyloidosis to understand how the disease is treated and what happens over time. It helps doctors learn more about this condition so they can improve care.
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
This study is observing people with amyloidosis or those who carry a specific gene mutation (transthyretin) to learn more about the condition. It does not test any new treatment, but may help researchers understand how the disease affects people.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
This study looks for “biomarkers” (measurable signs in blood or other tests) to understand inherited transthyretin amyloidosis, including in people who have not yet developed symptoms. Results may help researchers track the condition earlier and better understand how it changes over time.
Hear when a new ATTR Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.